Intracellular Th Stock Debt To Equity
| ITCI Stock | USD 131.60 0.07 0.05% |
Intracellular Th fundamentals help investors to digest information that contributes to Intracellular's financial success or failures. It also enables traders to predict the movement of Intracellular Stock. The fundamental analysis module provides a way to measure Intracellular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intracellular stock.
Intracellular |
Intracellular Th Company Debt To Equity Analysis
Intracellular's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Intracellular Debt To Equity | 0.04 % |
Most of Intracellular's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intracellular Th is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Intracellular Th has a Debt To Equity of 0.038%. This is 99.93% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 99.92% higher than that of the company.
Intracellular Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intracellular's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intracellular could also be used in its relative valuation, which is a method of valuing Intracellular by comparing valuation metrics of similar companies.Intracellular is currently under evaluation in debt to equity category among its peers.
Intracellular Fundamentals
| Return On Equity | -0.0858 | ||||
| Return On Asset | -0.0696 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 13 B | ||||
| Shares Outstanding | 106.33 M | ||||
| Shares Owned By Insiders | 2.47 % | ||||
| Shares Owned By Institutions | 96.78 % | ||||
| Number Of Shares Shorted | 2.31 M | ||||
| Price To Earning | (6.56) X | ||||
| Price To Book | 12.18 X | ||||
| Price To Sales | 20.54 X | ||||
| Revenue | 680.85 M | ||||
| Gross Profit | 387.77 M | ||||
| EBITDA | (116.72 M) | ||||
| Net Income | (74.68 M) | ||||
| Cash And Equivalents | 628.74 M | ||||
| Cash Per Share | 6.64 X | ||||
| Total Debt | 16.98 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 9.81 X | ||||
| Book Value Per Share | 10.81 X | ||||
| Cash Flow From Operations | (73.18 M) | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | (0.72) X | ||||
| Target Price | 132.0 | ||||
| Number Of Employees | 860 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 13.99 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.69 B) | ||||
| Working Capital | 1.1 B | ||||
| Current Asset | 541.82 M | ||||
| Current Liabilities | 140.69 M | ||||
| Net Asset | 1.37 B |
About Intracellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intracellular Th's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intracellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intracellular Th based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Intracellular Piotroski F Score and Intracellular Altman Z Score analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.